Click image to enlarge
U-PLEX Combos offer popular panels of biomarkers that have been grouped together for convenient ordering. They have been tested for multiplex compatibility and are fulfilled as a kit. The U-PLEX Chemokine Combo 2 (mouse) combines assays for 6 well-established chemokines (Table 1). The assays can be used for quantitative measurements in the sample types listed in the "Specifications" tab below, and offer detection limits (LLODs) in the sub- to low pg/mL range.
| Analyte | LLOD - ULOD | units |
| 6CKine/CCL21 | 1.5 - 4,000 | pg/mL |
| BCA-1/BLC | 21 - 32,000 | pg/mL |
| MCP-5/CCL12 | 0.14 - 1,500 | pg/mL |
| RANTES | 0.72 - 2,000 | pg/mL |
| SDF-1α | 8.1 - 50,000 | pg/mL |
| TARC | 0.32 - 1,200 | pg/mL |
-
-
Specifications
-
Kit Contents
-
-
Documentation
-
References
|
Application(s)
|
|
Cytokines & Chemokines
,
Immunology/Inflammation
|
|
|
Analyte(s)
|
|
6CKine/CCL21, BCA-1/BLC, MCP-5/CCL12, RANTES, SDF-1α, TARC
|
|
|
Species
|
|
Mouse
|
|
|
Instrument(s)
|
|
SECTOR Imager 2400
,
SECTOR Imager 6000
,
MESO QuickPlex SQ 120
,
MESO QuickPlex SQ 120MM
,
MESO SECTOR S 600
,
MESO SECTOR S 600MM
|
|
|
U-PLEX Group Compatibility
|
|
Biomarker Group 1
|
|
|
Plate Type
|
|
96-well
|
|
|
Sample Type
|
|
EDTA Plasma, Serum
|
|
|
Usage Statement
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
|
|
Storage Statement(s)
|
|
Please refer to the product insert for the storage conditions of individual kit components.
|
|
|
Storage Condition
|
|
Multi-Component
|
|
|
Schedule B Code
|
|
3822.19.0000
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
U-PLEX Linker Set, 6-Assay (300 µL)
|
2-8 °C
|
1 each
(1 vial)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(1 plate size)
|
|
|
|
|
≤-70 °C
|
1 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
1 vial
(1 vial)
|
|
|
|
U-PLEX 6-Assay, 96-Well SECTOR Plate
|
2-8 °C
|
1 each
(1 plate)
|
|
|
|
|
≤-10 °C
|
1 bottle
(10 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(8 mL)
|
|
|
|
U-PLEX Stop Solution
|
2-8 °C
|
1 bottle
(40 mL)
|
|
|
|
|
RT
|
1 bottle
(18 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
U-PLEX Linker Set, 6-Assay (1.8 mL)
|
2-8 °C
|
1 each
(1 vial)
|
|
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
1 each
(5 plate size)
|
|
|
|
|
≤-70 °C
|
5 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
5 vial
(1 vial)
|
|
|
|
U-PLEX 6-Assay, 96-Well SECTOR Plate
|
2-8 °C
|
5 each
(1 plate)
|
|
|
|
|
≤-10 °C
|
1 bottle
(50 mL)
|
|
|
|
|
≤-10 °C
|
1 bottle
(40 mL)
|
|
|
|
U-PLEX Stop Solution
|
2-8 °C
|
1 bottle
(40 mL)
|
|
|
|
|
RT
|
1 bottle
(90 mL)
|
|
|
|
Product Description
|
Storage
|
Quantity per Kit
|
|
U-PLEX Linker Set, 6-Assay (1.8 mL)
|
2-8 °C
|
5 each
(1 vial)
|
|
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
2-8 °C
|
5 each
(5 plate size)
|
|
|
|
|
≤-70 °C
|
25 vial
(1 vial)
|
|
|
|
|
2-8 °C
|
25 vial
(1 vial)
|
|
|
|
U-PLEX 6-Assay, 96-Well SECTOR Plate
|
2-8 °C
|
25 each
(1 plate)
|
|
|
|
|
≤-10 °C
|
5 bottle
(50 mL)
|
|
|
|
|
≤-10 °C
|
5 bottle
(40 mL)
|
|
|
|
U-PLEX Stop Solution
|
2-8 °C
|
5 bottle
(40 mL)
|
|
|
|
|
RT
|
5 bottle
(90 mL)
|
|
|
|
Product Inserts
|
|
|
|
Datasheets
|
|
|
|
Product Highlights
|
|
|
|
SDS
|
|
|
|
Title
|
Journal
|
Year
|
|
Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection
|
|
|
|
Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial
|
|
|
|
CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease
|
|
|
|
Stratum Corneum Tape Stripping: Monitoring of Inflammatory Mediators in Atopic Dermatitis Patients Using Topical Therapy.
|
|
|
|
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.
|
|
|
|
|
View All
|
Order Details
Catalog No
Size
Price in USD
Qty
Customer Service/Orders
Scientific/Technical Support
Instrument Support
Company Headquarters